Compare DFLI & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | SNTI |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 53.6M |
| IPO Year | N/A | N/A |
| Metric | DFLI | SNTI |
|---|---|---|
| Price | $3.38 | $1.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $22.50 | $9.00 |
| AVG Volume (30 Days) | ★ 725.8K | 288.7K |
| Earning Date | 11-14-2025 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $57,783,000.00 | N/A |
| Revenue This Year | $17.85 | N/A |
| Revenue Next Year | $30.29 | $150.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.24 | N/A |
| 52 Week Low | $1.50 | $1.02 |
| 52 Week High | $26.20 | $5.10 |
| Indicator | DFLI | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 37.65 |
| Support Level | $3.50 | $1.04 |
| Resistance Level | $4.55 | $1.19 |
| Average True Range (ATR) | 0.35 | 0.06 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 5.24 | 10.53 |
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.